Eledon Pharmaceuticals (ELDN) – 3Q26 Reported As Clinical Trial Preparations Continue


Monday, November 16, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 Expected Shortly. Eledon reported a 3Q26 loss of $3.9 million, or $(0.03) per share, including a non-cash gain of $17.0 million from the Changes in Fair Value of Warrant Liabilities. The Operating Loss of $21.7 million was consistent with our estimated $22.9 million operating expense. The Phase 3 LEGACY trial is expected to begin by YE2026, while the islet cell transplant trial has begun. Cash on hand on September 30, 2026, was $69.7 million.

Phase 3 LEGACY Trial Expected By YE2026. The Phase 3 LEGACY trial to prevent kidney transplant rejection is on schedule to begin during 4Q26. The primary endpoint in the trial is non-inferiority of a composite score of BPAR, graft loss, and death. The objective of the Phase 2 BESTOW trial was to characterize tegoprubart safety and efficacy, with these data points included as secondary endpoints. We continue to believe investors misunderstood the results.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Leave a Reply